Neuro-COVID-19: Neurological Complications of COVID-19

NCT04418609 | Completed

• 1 other identifier: Neuro-COVID-19
• Study Type: observational
• Target: 8
• Locations: 1 country
• Sites: 1

Brief Summary

The prevalence and typical patterns of neurological complications in hospitalized COVID-19 patients admitted to the intensive care units of the University Hospital Zurich will be investigated. The impact of neurological complications among COVID-19 patients on mortality, functional outcome, and organizational outcomes will be analyzed.

Conditions

Neurologic Complication

Outcome Measures

Primary Outcomes (5)

• Prevalence of neurological complications

  Determine the prevalence of neurological complications in hospitalized COVID-19 patients admitted to the intensive care unit.

  through study completion, on an average of 3 weeks

• Prevalence and outcome of severe neurological complications

  Examine if empiric COVID-19 therapies are associated with difference in the prevalence and outcome of severe neurological complications of COVID-19.

  through study completion, on an average of 3 weeks

• Impact of neurological complications

  Determine the impact of neurological complications among COVID-19 patients on mortality, functional outcome, and organizational outcomes (ICU length of stay, hospital length of stay) among patients with confirmed COVID-19.

  through study completion, on an average of 3 weeks

• Characteristic patterns in cerebral imaging and electroencephalography (EEG), as well as cerebrospinal fluid (CSF)

  Analyze characteristic patterns in cerebral imaging and electroencephalography (EEG), as well as cerebrospinal fluid (CSF) of patients, in whom a lumbar puncture has been performed for clinical reasons

  through study completion, on an average of 3 weeks

• Brain for pathological changes and histopathological findings (if patient dies).

  Analyze the brain for pathological changes and histopathological findings, if the patient dies.

  through study completion, on an average of 3 weeks

Interventions

further processing of health data OTHER

further processing of biological materials and health related personal data for research

Also known as: further processing of biological materials and health related personal data

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

All patients admitted to the Intensive Care Units (ICUs) of the Institute of Intensive Care Medicine, University Hospital of Zurich meeting eligibility criteria during the pandemic will be enrolled.

You may qualify if:

• Adults (age \> 18 years old) treated at ICUs
• Admitted with confirmed COVID-19 infection
• Patient exhibiting acute neurological manifestations
• General consent of the Institute of Intensive Care Medicine available from patient or legal representative

You may not qualify if:

• Pre-existing severe neurologic dysfunction

Sponsors & Collaborators

• Emanuela Keller: lead

Study Sites (1)

University Hospital Zurich

Zurich, 8091, Switzerland

Location

Study Officials

• Emanuela Keller, Prof. Dr.

  University Hospital, Zürich

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: OTHER
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Prof. Dr. Emanuela Keller

Study Record Dates

• First Submitted: May 28, 2020
• First Posted: June 5, 2020
• Study Start: May 1, 2020
• Primary Completion: June 9, 2022
• Study Completion: June 9, 2022
• Last Updated: August 4, 2022

Record last verified: 2022-08

Data Sharing

• IPD Sharing: Will not share

Locations

CH (1)